Incidence, treatment method and recurrence rate in giant cell granulomas: Retrospective study

Ilgin Ari; Selen Adiloglu; Alper Aktas; Göknur Topaloglu Yasan; Ecem Usman; Sena Aksoy

doi:10.1016/j.jcms.2024.03.011

Incidence, treatment method and recurrence rate in giant cell granulomas: Retrospective study

J Craniomaxillofac Surg. 2024 Mar 13:S1010-5182(24)00098-2. doi: 10.1016/j.jcms.2024.03.011. Online ahead of print.

Authors

Ilgin Ari¹, Selen Adiloglu², Alper Aktas², Göknur Topaloglu Yasan², Ecem Usman³, Sena Aksoy³

Affiliations

¹ Hacettepe University, Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Ankara, Turkey. Electronic address: ariilgin@gmail.com.
² Hacettepe University Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Ankara, Turkey.
³ Hacettepe University, Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Ankara, Turkey.

PMID: 38641523
DOI: 10.1016/j.jcms.2024.03.011

Abstract

Central and peripheral giant cell granulomas are benign entities mostly seen in mandibular anterior region at female individuals, usually with observed recurrence. Their etiology is still unclear, as is the optimal method for treating them. The aim of this study was to evaluate the incidence, treatment methods, recurrence rates, and initial and definitive correlation of central and peripheral giant cell granulomas. Patients who were referred to our clinic between 2013 and 2023 and who had the lesions' definitive diagnosis as "central giant cell granuloma" (CGCG) or "peripheral giant cell granuloma" (PGCG) were included in the study. Demographic data, recurrence rates, treatment methods, lesion location, clinical behaviors, and sizes were noted on the reports. A total of 30 lesions in 23 patients (14 PGCG and 9 CGCG) were evaluated in this study. The mean follow-up time was 62.6 months; 8 of 23 patients had systemic disease. While only 1 patient was observed to have cortical bone destruction in PCGC, all patients were found to have cortical bone destruction in CGCG (p < 0.05). In both lesions, the correlation of preliminary and definitive diagnosis was evaluated, and it was found to be 50% in PGCG while it was 77.7% in CGCG. The recurrence rates were 21.4% in PGCG and 33.3% in CGCG. Curettage was applied in all patients. Additional treatments (intralesional steroid injections, denasumab applications, resection, and graft application) were performed in 5 patients who were found to have CGCG (p = 0.004). However, there was no significant relation between treatment method and recurrence in CGCG (p > 0.05). Various peripheral lesions could mimic PGCG; thus, curettage therapy could be appropriate in the treatment of PGCG. Nevertheless, in some cases of CGCG, additional treatment methods could be more effective for preventing recurrence and any other complications.

Keywords: Central giant cell granuloma; Peripheral giant cell granuloma; Recurrence; Treatment options.